• Revenue growth outlook: Full-year revenue growth is projected to surpass last year's 23–24%, supported by broad-based client expansion and strong pipeline conversion that includes five deal wins above $1 million and one exceeding $3 million in ACV.
• EBITDA margin recovery: Margins are expected to return to the 19–20% range within six quarters, with recovery anticipated in the second half of the year toward Q4 FY27 as front-loaded investment impacts normalize.
• Employee productivity gains: Revenue per employee reached a record $77,100, supported sustainably by GenAI-embedded solutions and contracts structured around output- and outcome-based pricing models.
• Market diversification: While the US remains the primary innovator pharma market, the company is gaining traction across Europe, Japan, and China, while biotech client contributions have risen to approximately 3% of revenue.